Chinese PE Firm Huagai Capital To Close Huagai Medical Phase III Fund At $430M

Violet Tang
December 24, 2018 — 21:20 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing Beijing Science & Technology Innovation Fund biotech China chinese genome healthcare Hong Kong Huagai Capital Huagai Medical Phase III Fund insurance investment medicine pharmaceutical Private Equity stock market technology venture capital

Related News:

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

China To Expand Investment Scope for Its National Social Security Fund

December 8, 2023 — 00:03

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

China, With 1.4 Billion People, Faces Looming Demographic Crisis

February 18, 2021 — 04:48

What Are China’s Tech Giants: Alibaba, Tencent, Baidu, JD, Doing In Internet Healthcare?

January 30, 2021 — 05:58

Franchising and Licensing Asia (FLAsia) 2024